Ann: CEO Presentation , page-10

PeaceAkki,

According to the presentation the end of 2014/ Start of 2015 we will begin stage 1 trials. I agree that that seems a while away.
Despite this I think there will be rapid share price appreciation over the next 12 to 24 months for a number of reasons.

Cynata has a great shot at blue sky; • Meta-analysis shows MSCs are safe: review of
1,012 patients in 36 MSC clinical studies1
:
– “However, aside from fever, the published clinical trials
suggest that the administration of MSCs is safe”.
– “Although malignant transformation is a theoretical risk, … found no
association between MSCs and tumour formation”.
1
Lalu et al (2012): Safety of Cell Therapy with Mesenchymal Stromal Cells: A Systematic Review and Meta-analysis of Clinical Trials.
PLOS One 7(10): e47559

So we have 36 clinical grade articles published concluding the efficacy of MSC's. Couple this with
;• Outstanding pedigree: inventors on the WARF i.p. include James
Thomson who derived the first human embryonic stem (ES) cell line in
1998 and human induced pluripotent stem cells (iPSCs) in 2007.

So what we have is not just a clear inflection point in the biotech market in general - as seen by the US. But also a coming together of the marketing expertise and funding capabilities (Washer/Mcdonald) with VERY strong clinical evidence.

These things point to partnerships, non dilutive funding models etc. The team have done it before they are no strangers there. The other certainty is running multiple trials simultaneously.

I see no reason as to why this cant be a 100m company this time next year.